The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...